Supernus Pharmaceuticals Inc (SUPN) US$0.001

Sell:$32.21Buy:$41.85$2.57 (6.88%)

NASDAQ:1.35%
Market closed | Prices delayed by at least 15 minutes
Sell:$32.21
Buy:$41.85
Change:$2.57 (6.88%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$32.21
Buy:$41.85
Change:$2.57 (6.88%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Key people

Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
Timothy C. Dec
Chief Financial Officer, Senior Vice President
Padmanabh P. Bhatt
Senior Vice President - Intellectual Property, Chief Scientific Officer
Frank Mottola
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
Jonathan Rubin
Senior Vice President, Chief Medical Officer - Research and Development
Charles W. Newhall
Independent Chairman of the Board
Carrolee Barlow
Independent Director
Georges Gemayel
Independent Director
Frederick M. Hudson
Independent Director
Bethany L. Sensenig
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US8684591089
  • Market cap
    $2.06bn
  • Employees
    652
  • Shares in issue
    55.22m
  • Exchange
    NASDAQ
  • Index
    S&P 600 Small Cap, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.